FDA Grants Breakthrough Status to BeOne’s Sonrotoclax for Mantle Cell Lymphoma
BeOne Medicines has announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation (BTD) for sonrotoclax, an investigational BCL2 inhibitor, for adults with relapsed or refractory mantle cell lymphoma (MCL).
The medicine has also been accepted for review under Project Orbis, a programme supporting faster global assessment of oncology treatments.
The FDA decision is based on results from the Phase 1/2 BGB-11417-201 study, which is testing sonrotoclax in patients previously treated with a Bruton’s tyrosine kinase inhibitor and anti-CD20 therapy.
Early findings show strong and durable responses, suggesting potential as the first approved BCL2 inhibitor for this patient group in the United States. A Phase 3 confirmatory trial is currently in progress.
BTD is reserved for medicines showing early evidence of significant benefit in serious conditions. The Project Orbis initiative may enable quicker access to treatment in multiple countries.
This is the first BTD granted for sonrotoclax and the second within BeOne’s blood cancer pipeline. The therapy has already received Fast Track Designation for MCL and Waldenström macroglobulinaemia and Orphan Drug status in several B-cell malignancies.
MCL is an aggressive and rare form of non-Hodgkin lymphoma, accounting for around 5% of global cases.
Most patients eventually relapse, and current long-term survival remains limited, highlighting the need for new treatment options.
